The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 16.82 as of 02 Apr 15:30
. The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of March 2023
.The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023
. The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of March 2023
.The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023
. The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Mono Pharmacare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.
The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96.
The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.
About Mono Pharmacare Ltd
Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products.
The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing.
Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.
FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd
Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Mono Pharmacare Ltd?
Market cap of Bharat Immunological & Biological Corporation Ltd is 72 Cr while Market cap of Mono Pharmacare Ltd is 20 Cr
What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd?
The stock performance of Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd?
As of April 3, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹16.82. On the other hand, Mono Pharmacare Ltd stock price is INR ₹11.5.
How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd compare?
To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.